AOD-9604: The Fat Loss Fragment of Growth Hormone
A modified piece of human growth hormone that targets fat metabolism without the dangerous growth effects. What the clinical trials actually showed, how dosing works, and where it fits in the fat loss toolkit.
in Sequence
(Daltons)
Trial Stage
Australia (2010)
Growth hormone burns fat. That's been known for decades.
The problem? It also grows bones, organs, and tumors. Not exactly a clean trade-off for dropping a few pounds.
AOD-9604 was designed to fix that. Researchers took the fat-burning piece of human growth hormone, modified it slightly, and created a peptide that targets fat metabolism without the dangerous growth effects.
The result is one of the most studied fat loss peptides in history. Whether it works as well as early research suggested is a more complicated story.
This is an educational overview of AOD-9604 based on published research and clinical trial data. It is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
What Is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide consisting of 16 amino acids. It corresponds to the C-terminal fragment of human growth hormone (amino acids 176–191), with an added tyrosine residue at the N-terminus.
The peptide was originally developed at Monash University in Melbourne, Australia, during the 1990s. Metabolic Pharmaceuticals Ltd later licensed it and pushed it through clinical trials.
AOD-9604 at a Glance
| Feature | Detail |
|---|---|
| Type | Synthetic modified peptide fragment |
| Parent molecule | Human growth hormone (hGH) |
| Region | Amino acids 176–191 + tyrosine |
| Molecular weight | ~1,817 Da |
| Primary research focus | Fat metabolism, obesity |
| FDA status | Not approved |
| TGA status (Australia) | Approved as supplement ingredient |
How AOD-9604 Works
The basic idea is straightforward: isolate the fat-burning activity of growth hormone from everything else.
Lipolysis Without Growth
Full-length growth hormone triggers fat breakdown through its C-terminal region. AOD-9604 mimics this specific activity without stimulating IGF-1 or altering blood glucose.
Stimulates Lipolysis
Increases the breakdown of stored triglycerides in adipose tissue, releasing fatty acids for energy use.
Inhibits Lipogenesis
Reduces the formation of new fat from non-fat food sources like carbohydrates.
Critically, AOD-9604 does not raise IGF-1 levels. That means no growth-promoting effects on bones, organs, or tissues (Ng et al., 2000).
The Beta-3 Adrenergic Connection
Research suggests AOD-9604 works partly through the beta-3 adrenergic receptor pathway. This is the same pathway activated during cold exposure and exercise.
Beta-3 receptors sit primarily on fat cells. When activated, they increase cyclic AMP and hormone-sensitive lipase activity, prompting fat cells to release stored fatty acids into the bloodstream for burning (Heffernan et al., 2001).
AOD-9604 stimulated lipolysis in both human and animal fat tissue without any of the metabolic disruptions caused by full growth hormone treatment.
AOD-9604 vs. Full HGH: Side-by-Side
| Effect | Full HGH | AOD-9604 |
|---|---|---|
| Fat breakdown | Yes | Yes |
| IGF-1 elevation | Yes | No |
| Blood sugar increase | Yes | No |
| Bone/cartilage growth | Yes | No |
| Organ enlargement | Yes | No |
| Water retention | Yes | No |
| Carpal tunnel risk | Yes | No |
That clean separation is what made AOD-9604 attractive as a potential obesity drug in the first place (Ng and Borgeois, 2007).
Research History
AOD-9604 has a longer research timeline than most peptides in the fat loss space. The story starts in the early 1990s and includes both promising preclinical results and underwhelming clinical outcomes.
Preclinical Studies (1990s)
Researchers at Monash University first identified that the C-terminal fragment of growth hormone could reduce body fat in animal models. Obese mice treated with the hGH fragment lost significant body fat, while lean mice showed no abnormal weight loss (Ng et al., 2000).
No antibody formation against the peptide was detected, indicating low immunogenicity.
Obese Zucker Rat Studies
The Zucker rat is a genetic model of obesity. These animals develop severe obesity and metabolic dysfunction.
| Parameter | Result with AOD-9604 |
|---|---|
| Body weight | Significant reduction vs. controls |
| Fat mass | Reduced without lean mass loss |
| Food intake | No change (not an appetite suppressant) |
| IGF-1 levels | No increase |
| Blood glucose | No change |
AOD-9604 reduced fat without suppressing appetite. The mechanism is purely metabolic, not behavioral. This is an important distinction from GLP-1 drugs like semaglutide.
Phase 1 Clinical Trial
Metabolic Pharmaceuticals conducted a Phase 1 study in healthy volunteers in the early 2000s. AOD-9604 was well tolerated at multiple dose levels with no serious adverse events.
Pharmacokinetics supported once-daily oral dosing. No effects on IGF-1, insulin, or cortisol were observed.
Phase 2 Clinical Trials
The pivotal moment came with two Phase 2 trials in obese subjects.
Randomized, Double-Blind, Placebo-Controlled
| Parameter | Detail |
|---|---|
| Participants | 300 obese adults |
| Duration | 12 weeks |
| Route | Oral capsule |
| Doses tested | 1 mg, 5 mg, 10 mg, 20 mg daily |
| Group | Average Weight Loss | Significance |
|---|---|---|
| 1 mg | 1.6 kg | Statistically significant |
| 5 mg | Modest | Not significant |
| 10 mg | Modest | Not significant |
| 20 mg | Modest | Not significant |
| Placebo | 0.8 kg | Baseline |
The results were mixed. Only the lowest dose hit statistical significance, and the overall magnitude of weight loss was modest.
A larger Phase 2b trial followed with over 500 participants. Weight loss differences between AOD-9604 and placebo were small and inconsistent across dose groups.
The clinical trial results did not match the dramatic preclinical findings. AOD-9604 was safe, but fat loss in humans was modest at best when taken orally.
Why the Disconnect?
Oral Bioavailability
Peptides are notoriously difficult to absorb through the gut. Much of the oral dose may have been destroyed before reaching circulation.
Dose Optimization
The effective dose range may not have been identified. The inverted dose-response (lowest dose working best) suggests dosing was not well understood.
Species Differences
Rodent fat metabolism responds differently than human fat metabolism. Results in mice don't always translate to people.
Study Duration
Twelve weeks may not capture the full effect curve. Longer trials might have shown different results.
Metabolic Pharmaceuticals ultimately failed to secure further funding. The company ceased operations, and AOD-9604 never advanced to Phase 3 trials as a standalone obesity treatment.
Current Research and Applications
Despite the clinical trial setbacks, AOD-9604 didn't disappear. It found new life in several areas.
Cartilage Repair
Surprisingly, AOD-9604 showed potential in musculoskeletal research. In vitro studies showed increased proteoglycan and collagen synthesis in chondrocytes (Kwon et al., 2012).
Animal models of osteoarthritis showed reduced joint degeneration. Calithera Biosciences investigated intra-articular injections for knee osteoarthritis.
Australian TGA Approval
In 2010, the Australian Therapeutic Goods Administration approved AOD-9604 as a food substance. It can be included in over-the-counter supplements in Australia.
This was based on its demonstrated safety profile, not its efficacy as a weight loss agent.
Compounding Pharmacy Use
In the United States, AOD-9604 has become popular through compounding pharmacies and peptide clinics. It's typically prescribed as a subcutaneous injection rather than the oral form used in clinical trials.
The subcutaneous route bypasses the oral bioavailability problem, delivering the peptide directly into systemic circulation. Many practitioners believe this is why clinical users report better results than the oral trials suggested.
Dosing Protocols
These are research-based protocols commonly reported in clinical settings, not FDA-approved prescriptions. Always work with a qualified provider.
| Parameter | Detail |
|---|---|
| Dose range | 250–300 mcg per day |
| Frequency | Once daily |
| Route | Subcutaneous injection |
| Timing | Morning, on an empty stomach |
| Cycle length | 12–20 weeks |
| Common protocol | 300 mcg daily for 12 weeks, then reassess |
Why Fasted?
AOD-9604 is typically administered in a fasted state, at least 30 minutes before eating. Elevated insulin levels after meals may blunt the lipolytic effect.
This mirrors how growth hormone itself works. GH-mediated fat breakdown is suppressed when insulin is high.
Reconstitution
AOD-9604 comes as a lyophilized powder. For injection preparation, see the reconstitution guide.
| Step | Detail |
|---|---|
| Solvent | Bacteriostatic water |
| Volume | Typically 2–3 mL per 5 mg vial |
| Storage | Refrigerate after reconstitution |
| Shelf life | Use within 28 days once reconstituted |
Stacking
Some practitioners combine AOD-9604 with other peptides for fat loss. Here are the most common combinations.
| Stack | Purpose | Notes |
|---|---|---|
| AOD-9604 + CJC-1295/Ipamorelin | GH secretagogue support | Adds IGF-1 elevation |
| AOD-9604 + BPC-157 | Fat loss + tissue repair | Complementary mechanisms |
| AOD-9604 + Tesamorelin | Subcutaneous + visceral fat | Targets different fat stores |
Side Effects and Safety
AOD-9604 has one of the cleanest safety profiles in the peptide space. Clinical trials showed minimal adverse events compared to placebo.
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site irritation | Occasional | Mild redness, resolves quickly |
| Headache | Uncommon | Similar rates to placebo in trials |
| Mild nausea | Rare | Usually transient |
| Flu-like symptoms | Rare | Reported in early trial days only |
What Has Not Been Reported
Unlike full growth hormone, AOD-9604 has not been associated with blood sugar elevation, joint pain, water retention, carpal tunnel symptoms, or increased cancer risk markers.
Discontinue and consult a provider if you experience persistent injection site reactions, unusual swelling in extremities, or any signs of allergic reaction (difficulty breathing, hives, facial swelling).
The long-term safety profile beyond 12–24 weeks is not well characterized. Extended use should be monitored by a healthcare provider.
For a broader overview, see the peptide side effects guide.
AOD-9604 vs. Other Fat Loss Peptides
How does AOD-9604 stack up against the other options?
| Feature | AOD-9604 | Tesamorelin | Semaglutide | CJC-1295/Ipa |
|---|---|---|---|---|
| Mechanism | Direct lipolysis | GH release | GLP-1 appetite suppression | GH secretagogue |
| Weight loss | Modest | Moderate (visceral) | Significant (15–24%) | Mild-moderate |
| Appetite suppression | No | No | Strong | No |
| IGF-1 increase | No | Yes | No | Yes |
| FDA approved | No | Yes (HIV lipodystrophy) | Yes (obesity) | No |
| Side effects | Minimal | Moderate | GI-heavy | Mild-moderate |
| Cost | Low-moderate | High | Very high | Moderate |
Where AOD-9604 Fits
AOD-9604 occupies a specific niche. It's not the most powerful fat loss tool available. Semaglutide and tirzepatide clearly produce greater weight loss.
But it has advantages that matter to certain people.
No Appetite Changes
For those who don't want behavioral modification or the nausea that comes with GLP-1 drugs.
No GH-Related Risks
For those concerned about IGF-1 elevation, insulin resistance, or unwanted growth effects.
Minimal Side Effects
For those who can't tolerate GLP-1 drugs or who've had bad reactions to other peptides.
Lower Cost
Significantly cheaper than branded GLP-1 medications like Wegovy or Mounjaro.
AOD-9604 is a mild fat loss peptide with excellent tolerability. It's best suited for people seeking a modest metabolic boost rather than dramatic weight loss.
Legal Status and Availability
The legal status of AOD-9604 varies significantly by country.
TGA-Approved (2010)
Approved as a food/supplement ingredient. Available over the counter. Based on safety data, not efficacy as a weight loss agent.
Not FDA-Approved
Available through compounding pharmacies with a prescription. Also sold as a research chemical. Gray area after the FDA's 2023 peptide crackdown.
Not Approved
Regulatory status varies by member state. No centralized approval for therapeutic or supplement use.
Not Approved
Not approved for therapeutic use. Availability limited to research channels.
WADA Status
AOD-9604 is not explicitly listed on the World Anti-Doping Agency prohibited list. However, WADA's prohibition of growth hormone fragments could theoretically encompass it.
Athletes should exercise caution and consult with anti-doping authorities. Check the peptide legality guide for full details.
Frequently Asked Questions
What does AOD-9604 actually do?
How long does it take to see results?
Is AOD-9604 the same as HGH fragment 176-191?
Does AOD-9604 affect blood sugar?
Can I take AOD-9604 orally?
Is AOD-9604 safe long-term?
Can I combine AOD-9604 with GLP-1 drugs?
Why didn't AOD-9604 get FDA approval?
The Bottom Line
AOD-9604 is a peptide with a compelling theory behind it. Taking the fat-burning piece of growth hormone and stripping away the risks was a smart approach. The preclinical data was genuinely promising.
The human clinical data told a more restrained story. Oral AOD-9604 produced modest weight loss that didn't justify the investment needed for Phase 3 trials.
The peptide's second life as an injectable compound through clinics and compounding pharmacies may deliver better results. But that hasn't been validated in controlled trials.
For people looking for a low-risk, mild fat loss peptide with minimal side effects, AOD-9604 remains a reasonable option. For people seeking significant weight loss, the GLP-1 class (semaglutide, tirzepatide) offers far more proven results.
AOD-9604 isn't a failure. It's a niche tool. In the right context, niche tools still have value.
This article is for educational and informational purposes only. It is not medical advice and should not be treated as such. Always consult a qualified healthcare provider before starting any peptide protocol. The information presented here is based on published research and does not constitute an endorsement of any specific product or treatment.
References
Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278. PubMed
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2001;280(1):E127–E133. PubMed
Ng FM, Borgeois J. Human growth hormone fragment (AOD9604) does not stimulate growth or IGF-I secretion. Obes Res Clin Pract. 2007;1(1):51–57. PubMed
Kwon DR, Park GY, Lee SC. Treatment of full-thickness rotator cuff tendon tear using umbilical cord blood-derived mesenchymal stem cells and polydeoxyribonucleotides in a rabbit model. Stem Cells Int. 2012;2012:613–685. PubMed
Related reading:
What Are Peptides? Beginner's Guide · Semaglutide: Complete Weight Loss Guide · Peptide Side Effects: What to Know · Best Peptides for Fat Loss
For compound profiles and sourcing info, visit PeptideArc.